Biotechnology - Licensing, Anti-virals

Filter

Current filters:

LicensingAnti-virals

Popular Filters

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

Cytos out-licenses VLP platform for hep B infections to OnCore Biopharma

06-01-2015

Switzerland-based Cytos Biotechnology has executed an exclusive license agreement granting privately-held…

Anti-viralsBiotechnologyCytos BiotechnologyLicensingOnCore BioPharma

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Valneva licenses EB66 to IAVI for preventive HIV vaccine

02-10-2013

Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…

Anti-viralsBiotechnologyLicensingVaccinesValneva

Valneva enters deals with Delta-Vir

13-09-2013

Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…

Anti-viralsBiotechnologyDelta-VirLicensingOncologyValneva

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Immune Design and Medicago link up to develop flu vaccines

01-07-2013

Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Third deal for Ascletis, which gains China market rights from Janssen to a clinical stage HIV protease inhibitor

01-05-2013

USA and China-based biotech firm Ascletis Pharmaceuticals says it has licensed development, manufacturing…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologyJanssenJohnson & JohnsonLicensingTMC310911

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Silencing investor concerns? Alnylam achieves RNAi milestone

02-08-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

COMPANY SPOTLIGHT

Menarini

Back to top